(September 5, 2017) Researchers at the University of Pennsylvania recently uncovered a link between one’s resistance to common types of chemotherapy and one’s tumor BRCA1/2 mutation status. More specifically, they looked at both copies of the BRCA genes, one copy given by each parent. Until recently, it had been assumed that mutated BRCA gene left … Continued
(August 22, 2017) The Journal of Clinical Oncology recently published a study about the unmet need of genetic testing in women with breast and ovarian cancer. Women who fit eligibility criteria from the National Comprehensive Cancer Network (NCCN) took surveys focusing on discussions about genetic testing with a health professional, being advised to have genetic … Continued
(August 21, 2017) The US Food and Drug Administration (FDA) has granted full approval to olaparib tablets (Lynparza, AstraZeneca) for use as maintenance therapy for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have achieved a complete or partial response to platinum-based chemotherapy. This is not only a new indication for … Continued
(August 9, 2017) The International Journal of Cancer recently published an article on preliminary findings for two factors that influence one’s risk of ovarian cancer, namely the age at which a woman gives birth and the age at which she starts using oral contraceptives. The authors, including Celeste Leigh Pearce, PhD of OCRFA’s Scientific Advisory … Continued
(July 31, 2017) The National Comprehensive Cancer Network (NCCN), has updated and published guidelines for patients with ovarian cancer. There are two parts to the resource guide: The Guidelines for Patients and Quick Guides. The NCCN Guidelines for Patients is an in depth look at topics such as testing, stages of cancer, and treatments. There … Continued
(July 27, 2017) Earlier this week, in Nature Cell Biology, researchers at The Wistar Institute published their findings about a few strategies to treat clear cell carcinoma. Clear cell is a rare form of ovarian cancer that does not usually respond well to platinum-based chemotherapy, which leaves patients with few options. In most cases of … Continued
Largest private funder of ovarian cancer research recognizes top researchers and community leaders NEW YORK — Today, Ovarian Cancer Research Alliance (OCRFA), the nation’s leading ovarian cancer research, advocacy and patient support organization, announces this year’s winners of its research and survivor awards at its annual conference. OCRFA honors two outstanding researchers for their cutting-edge … Continued
(July 19, 2017) The United States Preventative Services Task Force (USPSTF) has once again recommended against screening for ovarian cancer in asymptomatic, average risk women. The draft statement, which was published on July 18th, does not apply to women who are positive for BRCA1 and BRCA2 genetic mutations, who have a higher risk of developing … Continued
(July 6, 2017) Clovis Oncology, Inc. recently announced topline data from the confirmatory phase 3 ARIEL3 trial of the drug rucaparib, which successfully achieved the primary endpoint of improved progression-free survival (PFS) by investigator review in each of the three populations studied. Read the press release from Clovis Oncology.
(June 30, 2017) Ten thousand women, most of whom are BRCA1 or BRCA2 positive, were analyzed by the University of Cambridge in order to find age specific risk for breast and ovarian cancers. The goal of the study, which was published in the Journal of the American Medical Association (JAMA), was to better enable clinicians … Continued
(June 23, 2017) A clinical trial published in the Journal of Clinical Oncology focused on a largely understudied area of cancer survivorship: chemotherapy-induced peripheral neuropathy (CIPN) in women. Forty seven percent of the 512 women in the trial reported CIPN an average of 6 years after their treatment ended. Symptoms of CIPN reported during the … Continued
(June 1, 2017) A study, published last month in Gynecologic Oncology, focused on an area of ovarian cancer that is rarely talked about: the quality of life (QOL) for long term survivors of advanced stage ovarian cancer. Woman surviving 8.5 years or longer, who had anywhere from 0 recurrences to multiple recurrences, were given surveys … Continued
Get email updates about research news, action alerts, and ways to join the fight.
